| 1 |
Hussein M, Aldridge S, Guerrero Urbano T, Nisbet A. The effect of 6 and 15 MV on intensity-modulated radiation therapy prostate cancer treatment: plan evaluation, tumour control probability and normal tissue complication probability analysis, and the theoretical risk of secondary induced malignancies. Br J Radiol 2012;85:423-32./
|
|
| 2 |
Park JM, Kim JI, Choi CH, Chie EK, Kim IH, Ye SJ. Photon energy-modulated radiotherapy: Monte Carlo simulation and treatment planning study. Med Phys 2012;39:1265-77./
|
|
| 3 |
Korah MP, Deyrup AT, Monson DK, et al. Anatomic tumor location infl uences the success of contemporary limb-sparing surgery and radiation among adults with soft tissue sarcomas of the extremities. Int J Radiat Oncol Biol Phys 2012;82:933-9./
|
|
| 4 |
Dickie CI, Griffi n AM, Parent AL, et al. The relationship between local recurrence and radiotherapy treatment volume for soft tissue sarcomas treated with external beam radiotherapy and function preservation surgery. Int J Radiat Oncol Biol Phys 2012;82:1528-34./
|
|
| 5 |
Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specifi c tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419-25./
|
|
| 6 |
Canadas-Garre M, Becerra-Massare P, Lopez de la Torre- Casares M, et al. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients. Ann Surg 2012;255:986-92./
|
|
| 7 |
Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012;13:671-8./
|
|
| 8 |
Jiang ZQ, Yang K, Komaki R, et al. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys 2012;83:332-9./
|
|
| 9 |
US National Institute of Health. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Institute of Health; c2012 [cited 2012 Sep 15]. Available from: http://clinicaltrials.gov/ct2/ home./
|
|
| 10 |
Trabert B, Wentzensen N, Yang HP, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 2012 May 3 [Epub]. http://dx.doi.org/10.1002/ijc.27623./
|
|